Prolonged use of bedaquiline in the treatment for MDR-TB in a child.

Bedaquiline (Bdq), a novel TB drug, is referred to the most effective drugs and used for the management of multidrug-resistant tuberculosis (MDR-TB). The drug produces a cardiotoxic effect, and its use is limited to six months. We describe a clinical observation of prolonged bedaquiline use in the treatment for MDR-TB using a restricted number of drugs, to which susceptibility was preserved, in a 12-year-old child.

[Estimation of the possibilities of using unified chemotherapy regimens in new cases of pulmonary tuberculosis in old-age children and adolescents].

A hundred and forty children aged 13 to 17 who had new-onset active pulmonary tuberculosis were examined. There was a predominance of infiltrative tuberculosis (63.6%) in the pattern of its clinical forms.

[Pulmonary tuberculosis in children and adolescents with hyperergic tuberculin susceptibility: clinical and X-ray characteristics and methods of detection].

The clinical characteristics of pulmonary tuberculosis and its detection methods were studied in patients with hyperergic (Group 1, n = 84) and another (Group 2, n = 75) tuberculin susceptibility. The groups were identical in clinical, X-ray, and laboratory characteristics. The major clinical forms were infiltrative (35.

[Tuberculin diagnosis in children with a family history of allergy].

Two hundred and eighteen Mycobacterium tuberculosis-infected children and adolescents aged 4 to 18 years were examined. Whether the patients and their relatives had a history of allergic reactions was ascertained. A complex of diagnostic studies is of great value in verifying the presence of concomitant allergic diseases.